LV13457B - Vaccine composition admixed with an alkylphosphatidylcholine - Google Patents

Vaccine composition admixed with an alkylphosphatidylcholine Download PDF

Info

Publication number: LV13457B
Authority: LV; Latvia
Prior art keywords: les; des; dans; est; une
Prior art date: 2003-11-17

Application number

LVP-06-70A

Other languages

English (en)

Latvian (lv)

Inventor

Jean Haensler

Original Assignee

Sanofi Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-17

Filing date

2006-05-15

Publication date

2007-01-20

2006-05-15 Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur

2007-01-20 Publication of LV13457B publication Critical patent/LV13457B/lv

Links

239000000203 mixture Substances 0.000 title claims abstract description 55
229960005486 vaccine Drugs 0.000 title claims abstract description 21
-1 ester derivative of phosphatidylcholine Chemical class 0.000 claims abstract description 27
108091007433 antigens Proteins 0.000 claims abstract description 23
239000000427 antigen Substances 0.000 claims abstract description 22
102000036639 antigens Human genes 0.000 claims abstract description 22
125000000217 alkyl group Chemical group 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
239000002671 adjuvant Substances 0.000 claims description 24
239000000839 emulsion Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
150000008105 phosphatidylcholines Chemical class 0.000 claims description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 4
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 4
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 4
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 4
239000005642 Oleic acid Substances 0.000 claims 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 4
235000021314 Palmitic acid Nutrition 0.000 claims 2
235000021355 Stearic acid Nutrition 0.000 claims 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
235000021313 oleic acid Nutrition 0.000 claims 2
239000008117 stearic acid Substances 0.000 claims 2
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 2
238000011260 co-administration Methods 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
241000699729 Muridae Species 0.000 description 27
102000004127 Cytokines Human genes 0.000 description 16
108090000695 Cytokines Proteins 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 15
150000002148 esters Chemical class 0.000 description 13
238000002965 ELISA Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000725 suspension Substances 0.000 description 12
238000002649 immunization Methods 0.000 description 11
230000003053 immunization Effects 0.000 description 11
108010074328 Interferon-gamma Proteins 0.000 description 10
150000002632 lipids Chemical class 0.000 description 10
239000004417 polycarbonate Substances 0.000 description 10
229940082150 encore Drugs 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
241000700605 Viruses Species 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
108010002616 Interleukin-5 Proteins 0.000 description 7
102000000743 Interleukin-5 Human genes 0.000 description 7
239000002502 liposome Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102000008070 Interferon-gamma Human genes 0.000 description 6
101710149951 Protein Tat Proteins 0.000 description 6
230000000694 effects Effects 0.000 description 6
229960003130 interferon gamma Drugs 0.000 description 6
239000012528 membrane Substances 0.000 description 6
229920000515 polycarbonate Polymers 0.000 description 6
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000003607 modifier Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 4
230000009471 action Effects 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
238000000527 sonication Methods 0.000 description 4
239000002023 wood Substances 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
206010046865 Vaccinia virus infection Diseases 0.000 description 3
238000013019 agitation Methods 0.000 description 3
230000003416 augmentation Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
208000007089 vaccinia Diseases 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
108010059892 Cellulase Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241001080024 Telles Species 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229940106157 cellulase Drugs 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
235000009973 maize Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000004224 protection Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
VNHGETRQQSYUGZ-UHFFFAOYSA-N 1-nitro-2-phenoxybenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OC1=CC=CC=C1 VNHGETRQQSYUGZ-UHFFFAOYSA-N 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
240000000489 Agave utahensis Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
229920008712 Copo Polymers 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108010028921 Lipopeptides Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
101710130262 Probable Vpr-like protein Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241001455617 Sula Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
JGENYNHRIOHZOP-UHFFFAOYSA-N ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCOP([O-])(=O)OCC[N+](C)(C)C JGENYNHRIOHZOP-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940045808 haemophilus influenzae type b Drugs 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
238000000034 method Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
101150093826 par1 gene Proteins 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
230000018448 secretion by cell Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241000007181 unidentified human coronavirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-06-70A 2003-11-17 2006-05-15 Vaccine composition admixed with an alkylphosphatidylcholine LV13457B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0313406A FR2862306B1 (fr)	2003-11-17	2003-11-17	Composition vaccinale

Publications (1)

Publication Number	Publication Date
LV13457B true LV13457B (en)	2007-01-20

Family

ID=34508504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-06-70A LV13457B (en)	2003-11-17	2006-05-15	Vaccine composition admixed with an alkylphosphatidylcholine

Country Status (23)

Country	Link
US (2)	US7344720B2 (de)
EP (1)	EP1696954B1 (de)
JP (1)	JP4638880B2 (de)
KR (1)	KR101136107B1 (de)
CN (1)	CN1882358B (de)
AT (1)	ATE412429T1 (de)
AU (1)	AU2004290943B2 (de)
BR (1)	BRPI0416670A (de)
CA (1)	CA2545086C (de)
CY (1)	CY1108498T1 (de)
DE (1)	DE602004017504D1 (de)
DK (1)	DK1696954T3 (de)
ES (1)	ES2311875T3 (de)
FR (1)	FR2862306B1 (de)
IL (1)	IL175573A (de)
LT (1)	LT5435B (de)
LV (1)	LV13457B (de)
NO (1)	NO20062779L (de)
PL (1)	PL1696954T3 (de)
PT (1)	PT1696954E (de)
SI (1)	SI1696954T1 (de)
WO (1)	WO2005049080A1 (de)
ZA (1)	ZA200603522B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100752990B1 (ko)	2006-08-02	2007-08-30	주식회사 대웅	나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) *	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
ES2615390T3 (es)	2008-03-05	2017-06-06	Sanofi Pasteur	Proceso para estabilizar una composición de vacuna que contiene adyuvante
WO2010130897A1 (fr) *	2009-05-14	2010-11-18	Sanofi Pasteur	Procédé de détoxification du lipopolysaccharide (lps) ou du lipide a des bactéries à gram-négatif
WO2010130896A2 (fr)	2009-05-14	2010-11-18	Sanofi Pasteur	Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
EP2430151B1 (de)	2009-05-14	2014-06-18	Sanofi Pasteur	Meningokokkenimpfstoff von lipooligosacchariden aus modifizierte immunotype l6 neisseria meninigitidis
EP2578974A1 (de)	2011-10-05	2013-04-10	Sanofi Pasteur Sa	Verfahrenslinie zur Herstellung von gefriergetrockneten Partikeln
JP5761143B2 (ja) *	2011-11-02	2015-08-12	株式会社リコー	撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) *	2012-11-29	2014-05-29	Antonius Arnoldus Christiaan Jacobs	Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
HUE048344T2 (hu)	2013-03-18	2020-08-28	Intervet Int Bv	Vakcina kérõdzõ védelmére Mannheimia haemolytica okozta tüdõgyulladás ellen
BR112016031039B1 (pt)	2014-07-21	2022-02-15	Sanofi Pasteur Sa	Dispositivo de alimentação de líquido para a geração de gotículas, linha de processo para a produção de partículas liofilizadas e processos para preparar uma composição de vacina compreendendo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6100064A (en)	1984-04-06	2000-08-08	Chiron Corporation	Secreted viral proteins useful for vaccines and diagnostics
FR2773156B1 (fr)	1997-12-26	2000-03-31	Biovacs Inc	Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
MXPA03002640A (es) *	2000-09-28	2003-06-19	Chiron Corp	Microparticulas para la distribucion de acidos nucleicos heterologos.
CA2428103C (en) *	2000-11-07	2015-06-09	Immunovaccine Technologies Inc.	Vaccines with enhanced immune response and methods for their preparation
US7303881B2 (en) *	2004-04-30	2007-12-04	Pds Biotechnology Corporation	Antigen delivery compositions and methods of use

2003
- 2003-11-17 FR FR0313406A patent/FR2862306B1/fr not_active Expired - Fee Related
2004
- 2004-11-15 ES ES04805451T patent/ES2311875T3/es not_active Expired - Lifetime
- 2004-11-15 CN CN2004800338756A patent/CN1882358B/zh not_active Expired - Fee Related
- 2004-11-15 DK DK04805451T patent/DK1696954T3/da active
- 2004-11-15 PT PT04805451T patent/PT1696954E/pt unknown
- 2004-11-15 AT AT04805451T patent/ATE412429T1/de active
- 2004-11-15 BR BRPI0416670 patent/BRPI0416670A/pt not_active IP Right Cessation
- 2004-11-15 DE DE200460017504 patent/DE602004017504D1/de not_active Expired - Lifetime
- 2004-11-15 US US10/989,154 patent/US7344720B2/en not_active Expired - Fee Related
- 2004-11-15 ZA ZA200603522A patent/ZA200603522B/en unknown
- 2004-11-15 KR KR1020067009520A patent/KR101136107B1/ko not_active Expired - Fee Related
- 2004-11-15 WO PCT/FR2004/002911 patent/WO2005049080A1/fr not_active Ceased
- 2004-11-15 PL PL04805451T patent/PL1696954T3/pl unknown
- 2004-11-15 AU AU2004290943A patent/AU2004290943B2/en not_active Ceased
- 2004-11-15 SI SI200430990T patent/SI1696954T1/sl unknown
- 2004-11-15 CA CA 2545086 patent/CA2545086C/en not_active Expired - Fee Related
- 2004-11-15 EP EP04805451A patent/EP1696954B1/de not_active Expired - Lifetime
- 2004-11-15 JP JP2006540508A patent/JP4638880B2/ja not_active Expired - Fee Related
2006
- 2006-05-11 IL IL175573A patent/IL175573A/en active IP Right Grant
- 2006-05-15 LV LVP-06-70A patent/LV13457B/lv unknown
- 2006-05-17 LT LT2006036A patent/LT5435B/lt not_active IP Right Cessation
- 2006-06-14 NO NO20062779A patent/NO20062779L/no not_active Application Discontinuation
2008
- 2008-01-09 US US11/971,751 patent/US7767658B2/en not_active Expired - Fee Related
- 2008-11-11 CY CY081101283T patent/CY1108498T1/el unknown

Also Published As

Publication number	Publication date
EP1696954A1 (de)	2006-09-06
US20050208060A1 (en)	2005-09-22
DE602004017504D1 (de)	2008-12-11
LT2006036A (en)	2007-05-25
FR2862306A1 (fr)	2005-05-20
US7767658B2 (en)	2010-08-03
IL175573A0 (en)	2006-09-05
CN1882358B (zh)	2011-02-02
ZA200603522B (en)	2007-07-25
CA2545086C (en)	2011-11-08
AU2004290943B2 (en)	2009-08-27
US20080131446A1 (en)	2008-06-05
ATE412429T1 (de)	2008-11-15
CN1882358A (zh)	2006-12-20
CA2545086A1 (en)	2005-06-02
EP1696954B1 (de)	2008-10-29
PL1696954T3 (pl)	2009-04-30
WO2005049080B1 (fr)	2005-09-01
LT5435B (lt)	2007-07-25
BRPI0416670A (pt)	2007-02-13
DK1696954T3 (da)	2009-02-23
US7344720B2 (en)	2008-03-18
PT1696954E (pt)	2008-11-25
FR2862306B1 (fr)	2008-05-30
IL175573A (en)	2010-06-30
JP4638880B2 (ja)	2011-02-23
AU2004290943A1 (en)	2005-06-02
JP2007511585A (ja)	2007-05-10
ES2311875T3 (es)	2009-02-16
KR101136107B1 (ko)	2012-04-17
NO20062779L (no)	2006-08-15
KR20060127385A (ko)	2006-12-12
CY1108498T1 (el)	2014-04-09
WO2005049080A1 (fr)	2005-06-02
SI1696954T1 (sl)	2009-04-30

Publication	Publication Date	Title
EP1326636B1 (de)	2007-01-03	Impfstoffzusammesetzung
US7767658B2 (en)	2010-08-03	Vaccine composition
WO2005060966A1 (fr)	2005-07-07	Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4
WO2023147091A1 (en)	2023-08-03	Coronavirus vaccine
US20240115693A1 (en)	2024-04-11	Sars-cov-2 antigen nanoparticles and uses there of
Kawai et al.	2024	Lipid nanoparticle with 1, 2-Di-O-octadecenyl-3-trimethylammonium-propane as a component lipid confers potent responses of Th1 cells and antibody against vaccine antigen
EP0015810B1 (de)	1984-02-29	N-Acetyl-L-(N-methyl-alanyl)-D-isoglutamin sowie Gemische, die diese Verbindung enthalten, zur Regulierung der Immunreaktionen
JP2024517642A (ja)	2024-04-23	ウイルスワクチン
US20100047329A1 (en)	2010-02-25	Novel Vaccination Carrier
CN1200736C (zh)	2005-05-11	肝炎治疗剂
AU769390B2 (en)	2004-01-22	Vaccine composition
WO1989005631A1 (fr)	1989-06-29	Compositions presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
CA2406949A1 (fr)	2001-11-01	Utilisation de vecteurs particulaires dans l'immunomodulation
US20230321230A1 (en)	2023-10-12	Compositions and Methods for Adjuvanted Vaccines
CA2630530C (fr)	2016-03-29	Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral
HK40102659A (zh)	2024-06-07	病毒疫苗
WO2004103408A2 (fr)	2004-12-02	Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal
FR2881050A1 (fr)	2006-07-28	Dcchol chez les nouveaux-nes
WO2004073596A2 (fr)	2004-09-02	Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires.